Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 525-534
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.525
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.525
Table 1 Currently used direct aging antiviral characteristics
Trade name | Compound | Year of FDA/EMA approval | Mechanism of action | Pharmaceutical form | Dose | Genotypes |
Zepatier | Elbasvir/grazoprevir | 2016 | NS5A inhibitor/protease inhibitor | Film-coated tablet | 50 mg/100 mg qd | 1a, 1b, 4 |
Epclusa | Sofosbuvir/velpatasvir | 2016 | NS5B inhibitor/ NS5A inhibitor | Film-coated tablet | 400 mg/100 mg | Pangenotypic |
Maviret | Glecaprevir/pibrentasvir | 2017 | Protease inhibitor/NS5A inhibitor | Film-coated tablet | 100 mg/40 mg qd | Pangenotypic |
Vosevi | Sofosbuvir/velpatasvir/voxilaprevir | 2018/2017 | NS5B inhibitor /NS5A inhibitor/protease inhibitor | Film-coated tablet | 400 mg/100 mg/100 mg | Pangenotypic |
- Citation: Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/525.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.525